EN
SINOVAC's Influenza Vaccine (Split Virion), Inactivated (MDCK Cell) Granted Clinical Trial Approval
May 27, 2026 — SINOVAC has received approval from the National Medical Products Administration (NMPA) to launch clinical trials for its Influenza Vaccine (Split Virion), Inactivated (MDCK cell). The Phase I clinical research of the vaccine is scheduled to kick off in 2026.
Influenza remains a major global public health threat. According to the World Health Organization (WHO), around a billion cases of seasonal influenza are reported annually, including 3–5 million cases of severe illness.1 Vaccination stands as the most cost-effective approach to prevent the disease, which helps reduce influenza infections as well as associated complications, hospitalizations, and deaths.
To date, SINOVAC’s seasonal influenza vaccines have been widely distributed in about 20 countries and regions worldwide, with a cumulative supply exceeding 120 million doses. In December 2025, the vaccine obtained marketing approval in the United Arab Emirates (UAE). The first batch was shipped to the UAE in April, marking SINOVAC’s first delivery of influenza vaccines to Gulf Cooperation Council (GCC) member states. Additionally, SINOVAC has been the exclusive supplier for Chile’s national influenza vaccine procurement program for two consecutive seasons (2025–2026), supporting the country’s influenza prevention and control efforts.
SINOVAC continues to invest in the research and development of influenza vaccines. The company has advanced clinical development across multiple technical platforms, striving to bolster influenza prevention and control worldwide.
Reference:
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.